A trial looking at radiotherapy treatment for non Hodgkin lymphoma

Cancer type:

Blood cancers
High grade lymphoma
Low grade lymphoma
Non-Hodgkin lymphoma




Phase 3

This trial compared 2 different doses of radiotherapy to treat people with non Hodgkin lymphoma (NHL).

Doctors often treat non Hodgkin lymphoma with radiotherapy. All cancer treatment has side effects, and doctors are aware that problems can be caused by giving too much treatment as well as by giving too little.

The aim of the trial was to find out if a lower dose of radiotherapy was better than the standard dose and caused fewer side effects.

Summary of results

The trial team found that there was no difference between the lower dose of radiotherapy and the standard dose for treating non Hodgkin’s lymphoma (NHL).

This trial recruited 998 people.  It was a randomised trial. The people taking part were put into 1 of 2 groups.  The groups were those having

  • Standard dose of radiotherapy
  • Lower dose of radiotherapy   

If their NHL was in more than 1 area of the body, the trial team were allowed to randomise these people again. This is because they could have radiotherapy to more than 1 area of the body. This happened to 3 people. So the total number of results the trial team looked at was 1,001.

Of the 1,001 results the trial team looked at

  • For  783 there was no sign of NHL – complete response Open a glossary item
  • In 95 the NHL had got smaller – partial response Open a glossary item
  • In 75 the NHL had stayed the same or got worse
  • 7 could not be assessed
  • In 27 the results were missing

Ten people didn’t have radiotherapy and sadly 4 people died from their NHL.  

The trial team found no significant difference between the side effects of the 2 groups, apart from reddening or darkening of the skin in the treatment area.  This was less for people who had the lower dose of radiotherapy.

The trial team concluded that a lower dose of radiotherapy was as good as the standard dose of radiotherapy for treating non Hodgkin lymphoma.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Peter Hoskin

Supported by

Haematology Trials Group
Lymphoma Research Trust
NIHR Clinical Research Network: Cancer

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 89

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page